CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,396 enrolled
Drug / intervention
Tiotropium bromide plus Olodateroldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04672941
NCT04672941N/ACompleted
CompareCT.gov

Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva® Handihaler®) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto® Respimat®) Under Real Life Conditions in Greece (ELLACTO II Study)

Boehringer Ingelheim·observational·Posted Dec 17, 2020·Updated Jun 25, 2024

In Brief

An observational study evaluating Tiotropium bromide plus Olodaterol for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,396 participants across 2 sites.

Detailed Summary

The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartFeb 16, 2021
Primary CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.5 years ago

Interventions

Tiotropium bromide plus Olodateroldrug

Tiotropium bromide plus Olodaterol